EA009463B1 - Применение эритропоэтина - Google Patents
Применение эритропоэтина Download PDFInfo
- Publication number
- EA009463B1 EA009463B1 EA200500281A EA200500281A EA009463B1 EA 009463 B1 EA009463 B1 EA 009463B1 EA 200500281 A EA200500281 A EA 200500281A EA 200500281 A EA200500281 A EA 200500281A EA 009463 B1 EA009463 B1 EA 009463B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- erythropoietin
- cells
- endothelial
- use according
- pharmaceutical composition
- Prior art date
Links
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims abstract description 168
- 102000003951 Erythropoietin Human genes 0.000 claims abstract description 161
- 108090000394 Erythropoietin Proteins 0.000 claims abstract description 161
- 229940105423 erythropoietin Drugs 0.000 claims abstract description 161
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 33
- 230000029663 wound healing Effects 0.000 claims abstract description 16
- 208000009304 Acute Kidney Injury Diseases 0.000 claims abstract description 15
- 208000033626 Renal failure acute Diseases 0.000 claims abstract description 15
- 201000011040 acute kidney failure Diseases 0.000 claims abstract description 15
- 208000012998 acute renal failure Diseases 0.000 claims abstract description 15
- 210000002889 endothelial cell Anatomy 0.000 claims description 69
- 210000004027 cell Anatomy 0.000 claims description 57
- 208000020832 chronic kidney disease Diseases 0.000 claims description 41
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 36
- 241001465754 Metazoa Species 0.000 claims description 34
- 229940088623 biologically active substance Drugs 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 25
- 230000037396 body weight Effects 0.000 claims description 16
- 230000003442 weekly effect Effects 0.000 claims description 16
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 13
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 10
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 10
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 10
- 229960005370 atorvastatin Drugs 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 229960002855 simvastatin Drugs 0.000 claims description 10
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 10
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims description 9
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims description 9
- 229950009116 mevastatin Drugs 0.000 claims description 9
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims description 9
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 claims description 7
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 claims description 7
- 102000044890 human EPO Human genes 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 6
- 210000002700 urine Anatomy 0.000 claims description 6
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 claims description 5
- 108090000854 Oxidoreductases Proteins 0.000 claims description 5
- 102100035194 Placenta growth factor Human genes 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 4
- 229930064664 L-arginine Natural products 0.000 claims description 4
- 235000014852 L-arginine Nutrition 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 210000003714 granulocyte Anatomy 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 210000004408 hybridoma Anatomy 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 108020004511 Recombinant DNA Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 230000001684 chronic effect Effects 0.000 abstract description 5
- 210000000130 stem cell Anatomy 0.000 description 139
- 230000003511 endothelial effect Effects 0.000 description 131
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 66
- 201000010099 disease Diseases 0.000 description 59
- 210000003734 kidney Anatomy 0.000 description 48
- 210000001519 tissue Anatomy 0.000 description 48
- 230000004069 differentiation Effects 0.000 description 39
- 208000027418 Wounds and injury Diseases 0.000 description 33
- 230000004064 dysfunction Effects 0.000 description 32
- 206010052428 Wound Diseases 0.000 description 30
- 230000035755 proliferation Effects 0.000 description 26
- 230000015572 biosynthetic process Effects 0.000 description 25
- 108010019673 Darbepoetin alfa Proteins 0.000 description 24
- 208000019622 heart disease Diseases 0.000 description 24
- 229940115115 aranesp Drugs 0.000 description 23
- 239000000126 substance Substances 0.000 description 23
- 210000004204 blood vessel Anatomy 0.000 description 22
- 210000003038 endothelium Anatomy 0.000 description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 21
- 206010019280 Heart failures Diseases 0.000 description 18
- 241000700159 Rattus Species 0.000 description 18
- 230000002491 angiogenic effect Effects 0.000 description 18
- 210000000056 organ Anatomy 0.000 description 18
- 238000002054 transplantation Methods 0.000 description 18
- 230000005012 migration Effects 0.000 description 16
- 238000013508 migration Methods 0.000 description 16
- 208000029078 coronary artery disease Diseases 0.000 description 15
- 239000002243 precursor Substances 0.000 description 15
- 230000002792 vascular Effects 0.000 description 15
- 210000001367 artery Anatomy 0.000 description 14
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 14
- 230000006698 induction Effects 0.000 description 14
- 230000004862 vasculogenesis Effects 0.000 description 14
- 208000001647 Renal Insufficiency Diseases 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 201000006370 kidney failure Diseases 0.000 description 13
- 206010012601 diabetes mellitus Diseases 0.000 description 11
- 230000001404 mediated effect Effects 0.000 description 11
- 208000031225 myocardial ischemia Diseases 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 230000004936 stimulating effect Effects 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 10
- 230000000982 vasogenic effect Effects 0.000 description 10
- 206010002383 Angina Pectoris Diseases 0.000 description 9
- 206010020772 Hypertension Diseases 0.000 description 9
- 229940123934 Reductase inhibitor Drugs 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000036732 histological change Effects 0.000 description 9
- 208000028867 ischemia Diseases 0.000 description 9
- 210000005087 mononuclear cell Anatomy 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 210000002216 heart Anatomy 0.000 description 8
- 230000001771 impaired effect Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 208000019553 vascular disease Diseases 0.000 description 8
- 208000035150 Hypercholesterolemia Diseases 0.000 description 7
- 206010029113 Neovascularisation Diseases 0.000 description 7
- 208000012322 Raynaud phenomenon Diseases 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 229940109239 creatinine Drugs 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 230000003907 kidney function Effects 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 201000001320 Atherosclerosis Diseases 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 206010058116 Nephrogenic anaemia Diseases 0.000 description 6
- 208000003782 Raynaud disease Diseases 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 208000037976 chronic inflammation Diseases 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 210000003709 heart valve Anatomy 0.000 description 6
- 230000000302 ischemic effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000002107 myocardial effect Effects 0.000 description 6
- 201000011461 pre-eclampsia Diseases 0.000 description 6
- 102100022987 Angiogenin Human genes 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 206010038802 Reticuloendothelial system stimulated Diseases 0.000 description 5
- 206010047115 Vasculitis Diseases 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 108010072788 angiogenin Proteins 0.000 description 5
- 230000036770 blood supply Effects 0.000 description 5
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 238000002513 implantation Methods 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 238000010254 subcutaneous injection Methods 0.000 description 5
- 239000007929 subcutaneous injection Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 108050009340 Endothelin Proteins 0.000 description 4
- 102000002045 Endothelin Human genes 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 208000007502 anemia Diseases 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 208000029185 blood vessel neoplasm Diseases 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 208000023589 ischemic disease Diseases 0.000 description 4
- 229960003299 ketamine Drugs 0.000 description 4
- 208000017169 kidney disease Diseases 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 210000002254 renal artery Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- 206010048554 Endothelial dysfunction Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 206010047139 Vasoconstriction Diseases 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000008694 endothelial dysfunction Effects 0.000 description 3
- 230000008753 endothelial function Effects 0.000 description 3
- 230000001631 hypertensive effect Effects 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 238000013059 nephrectomy Methods 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- -1 respectively Chemical compound 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000025033 vasoconstriction Effects 0.000 description 3
- 241000234282 Allium Species 0.000 description 2
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000037157 Azotemia Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 210000001956 EPC Anatomy 0.000 description 2
- 206010063560 Excessive granulation tissue Diseases 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 206010070538 Gestational hypertension Diseases 0.000 description 2
- 208000022461 Glomerular disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 201000005624 HELLP Syndrome Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 208000005347 Pregnancy-Induced Hypertension Diseases 0.000 description 2
- 206010072170 Skin wound Diseases 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 210000002565 arteriole Anatomy 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000011990 functional testing Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000001126 granulation tissue Anatomy 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 201000009925 nephrosclerosis Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 208000036335 preeclampsia/eclampsia 1 Diseases 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 208000009852 uremia Diseases 0.000 description 2
- 206010055031 vascular neoplasm Diseases 0.000 description 2
- 230000006442 vascular tone Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 201000003126 Anuria Diseases 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000009738 Connective Tissue Neoplasms Diseases 0.000 description 1
- 206010052895 Coronary artery insufficiency Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000002087 Endarteritis Diseases 0.000 description 1
- 206010015124 Ergot poisoning Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000023329 Gun shot wound Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- 208000020858 L1 syndrome Diseases 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 206010024119 Left ventricular failure Diseases 0.000 description 1
- 201000002961 MASA syndrome Diseases 0.000 description 1
- 208000004221 Multiple Trauma Diseases 0.000 description 1
- 208000023637 Multiple injury Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000018525 Postpartum Hemorrhage Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 206010037601 Pyelonephritis chronic Diseases 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 206010039163 Right ventricular failure Diseases 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 208000026723 Urinary tract disease Diseases 0.000 description 1
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 108010022164 acetyl-LDL Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 210000000648 angioblast Anatomy 0.000 description 1
- 230000001656 angiogenetic effect Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000008321 arterial blood flow Effects 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000007214 atherothrombosis Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000002561 chemical irritant Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 201000006368 chronic pyelonephritis Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000008473 connective tissue growth Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000004665 defense response Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 208000006852 ergotism Diseases 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 201000007249 familial juvenile hyperuricemic nephropathy Diseases 0.000 description 1
- 108010046015 ferritin receptor Proteins 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 1
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 208000008384 ileus Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- FDMQDKQUTRLUBU-UHFFFAOYSA-N n-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]thieno[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(SC=C2)C2=N1 FDMQDKQUTRLUBU-UHFFFAOYSA-N 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000003924 normoblast Anatomy 0.000 description 1
- 229950000778 olmutinib Drugs 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000007847 structural defect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000005919 time-dependent effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10234192A DE10234192B4 (de) | 2002-07-26 | 2002-07-26 | Verwendung von Erythropoetin |
| PCT/EP2003/008229 WO2004012759A2 (de) | 2002-07-26 | 2003-07-25 | Erythropoetin zur stimulation endothelialer voläuferzellen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200500281A1 EA200500281A1 (ru) | 2005-06-30 |
| EA009463B1 true EA009463B1 (ru) | 2007-12-28 |
Family
ID=30128436
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200500281A EA009463B1 (ru) | 2002-07-26 | 2003-07-25 | Применение эритропоэтина |
| EA200801236A EA200801236A1 (ru) | 2002-07-26 | 2003-07-25 | Применение эритропоэтина |
| EA200700196A EA013966B1 (ru) | 2002-07-26 | 2003-07-25 | Применение эритропоэтина для лечения сахарного диабета |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200801236A EA200801236A1 (ru) | 2002-07-26 | 2003-07-25 | Применение эритропоэтина |
| EA200700196A EA013966B1 (ru) | 2002-07-26 | 2003-07-25 | Применение эритропоэтина для лечения сахарного диабета |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US7745387B2 (enExample) |
| EP (3) | EP1526867B1 (enExample) |
| JP (4) | JP4727988B2 (enExample) |
| KR (2) | KR20100077033A (enExample) |
| CN (3) | CN101099860B (enExample) |
| AT (2) | ATE468132T1 (enExample) |
| AU (2) | AU2003255290B2 (enExample) |
| BR (1) | BR0312981A (enExample) |
| CA (2) | CA2493598A1 (enExample) |
| CY (2) | CY1108052T1 (enExample) |
| DE (3) | DE10234192B4 (enExample) |
| DK (2) | DK1779862T3 (enExample) |
| EA (3) | EA009463B1 (enExample) |
| ES (2) | ES2345673T3 (enExample) |
| HR (3) | HRP20100187A2 (enExample) |
| IL (2) | IL166401A0 (enExample) |
| IS (3) | IS2671B (enExample) |
| MX (1) | MXPA05001120A (enExample) |
| NO (1) | NO20051002L (enExample) |
| PL (2) | PL395151A1 (enExample) |
| PT (2) | PT1779862E (enExample) |
| SG (1) | SG177004A1 (enExample) |
| SI (2) | SI1779862T1 (enExample) |
| UA (2) | UA85997C2 (enExample) |
| WO (1) | WO2004012759A2 (enExample) |
| ZA (1) | ZA200500726B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2642302C1 (ru) * | 2009-08-13 | 2018-01-24 | Акселерон Фарма Инк. | Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7199102B2 (en) | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US7723303B2 (en) | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| DE10234192B4 (de) * | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
| ATE513555T1 (de) * | 2003-07-29 | 2011-07-15 | Dompe Spa | Pharmazeutische kombination aus g-csf und plgf für blutstammzellen |
| BRPI0418326A (pt) * | 2003-12-30 | 2007-05-02 | Bionethos Holding Gmbh | método de regeneração de tecidos |
| DE102004063927A1 (de) * | 2004-01-23 | 2005-12-15 | Epoplus Gmbh Co.Kg | Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden |
| CA2595067A1 (en) | 2004-12-06 | 2006-06-15 | The Regents Of The University Of California | Methods for improving the structure and function of arterioles |
| AR053416A1 (es) | 2005-11-10 | 2007-05-09 | Protech Pharma S A | Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| EP3269381B1 (en) | 2005-11-23 | 2020-10-07 | Acceleron Pharma, Inc. | Activin-actriia antagonists in use for promoting bone growth |
| NZ573792A (en) * | 2006-06-07 | 2011-09-30 | Univ Tokushima | Treatment of ischemic disease using erythropoietin mobilised mononuclear cells |
| UA98472C2 (ru) * | 2006-09-29 | 2012-05-25 | Сентокор Орто Байотек Инк. | Применение агониста рецептора epo человека для лечения интолерантности к глюкозе |
| US8975374B2 (en) * | 2006-10-20 | 2015-03-10 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient |
| EP2078731A4 (en) * | 2006-10-20 | 2012-08-01 | Forerunner Pharma Res Co Ltd | ANTI-HB-EGF ANTIBODY AS PHARMACEUTICAL COMPOSITION CONTAINING ACTIVE SUBSTANCE |
| AU2007311946A1 (en) | 2006-10-20 | 2008-04-24 | Forerunner Pharma Research Co., Ltd. | Anti-cancer agent comprising anti-HB-EGF antibody as active ingredient |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| AU2008205263A1 (en) * | 2007-01-10 | 2008-07-17 | Edison Pharmaceuticals, Inc. | Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity |
| TW201907946A (zh) | 2007-02-02 | 2019-03-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| AR065613A1 (es) * | 2007-03-09 | 2009-06-17 | Chugai Pharmaceutical Co Ltd | Agentes de proteccion para organos transplantados |
| PL2192907T3 (pl) * | 2007-08-16 | 2018-10-31 | Remedor Biomed Ltd. | Kompozycje erytropoetyny i fibronektyny do zastosowań terapeutycznych |
| CA2724841A1 (en) * | 2008-05-22 | 2009-11-26 | Edison Pharmaceuticals, Inc. | Treatment of mitochondrial diseases with an erythropoietin mimetic |
| PT3494986T (pt) | 2008-08-14 | 2020-07-14 | Acceleron Pharma Inc | Armadilhas para gdf |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| MX2011013172A (es) | 2009-06-08 | 2012-04-02 | Acceleron Pharma Inc | Metodos para aumentar adipocitos termogenicos. |
| JP2012529294A (ja) | 2009-06-12 | 2012-11-22 | アクセルロン ファーマ， インコーポレイテッド | 切断型ＡｃｔＲＩＩＢ−Ｆｃ融合タンパク質 |
| CA2781152A1 (en) | 2009-11-17 | 2011-05-26 | Acceleron Pharma Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| DK2590666T3 (en) | 2010-07-06 | 2017-07-17 | Augustinus Bader | TOPICAL APPLICATION OF ERYTHROPOIETIN FOR USE IN THE TREATMENT OF DAMAGE OF THE CORNS |
| US9956265B2 (en) | 2011-04-26 | 2018-05-01 | Ajou University Industry-Academic Cooperation Foundation | Composition for aiding surgical procedures for treating ischemic vascular diseases |
| ES2884095T3 (es) | 2012-11-02 | 2021-12-10 | Celgene Corp | Antagonistas de activina-actrii y usos para el tratamiento de trastornos óseos y otros trastornos |
| US8992951B2 (en) | 2013-01-09 | 2015-03-31 | Sapna Life Sciences Corporation | Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma |
| US20160279297A1 (en) * | 2013-10-22 | 2016-09-29 | ConcieValve LLC | Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis |
| MA40008A (fr) | 2014-06-13 | 2021-05-05 | Acceleron Pharma Inc | Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie |
| EP4406585A3 (en) | 2015-02-13 | 2024-10-23 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
| CN105233256A (zh) * | 2015-10-28 | 2016-01-13 | 中国人民解放军第三军医大学 | 促红细胞生成素及其衍生物在制备治疗疾病中促进凋亡细胞清除的药物中的应用 |
| US11534466B2 (en) * | 2016-03-09 | 2022-12-27 | Aal Scientifics, Inc. | Pancreatic stem cells and uses thereof |
| GB2550114A (en) * | 2016-05-03 | 2017-11-15 | Kymab Ltd | Methods, regimens, combinations & antagonists |
| WO2018035377A1 (en) | 2016-08-17 | 2018-02-22 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
| CN108114282B (zh) * | 2016-11-28 | 2021-03-02 | 北京大学第三医院 | 他汀类化合物治疗缺血性疾病的用途 |
| JP7185884B2 (ja) | 2017-05-02 | 2022-12-08 | 国立研究開発法人国立精神・神経医療研究センター | Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法 |
| US11692037B2 (en) | 2017-10-20 | 2023-07-04 | Hyogo College Of Medicine | Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion |
| RU2695334C1 (ru) * | 2018-09-25 | 2019-07-23 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ профилактики нарушений функций почек карбамилированным дарбэпоэтином в эксперименте |
| RU2678768C1 (ru) * | 2018-09-25 | 2019-02-01 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ профилактики ишемически-реперфузионных повреждений почек карбамилированным дарбэпоэтином в эксперименте |
| AU2020301036A1 (en) | 2019-07-03 | 2022-02-17 | Factor Bioscience Inc. | Cationic lipids and uses thereof |
| US10501404B1 (en) | 2019-07-30 | 2019-12-10 | Factor Bioscience Inc. | Cationic lipids and transfection methods |
| CN119080909A (zh) * | 2024-08-29 | 2024-12-06 | 深圳赛保尔生物药业有限公司 | 负载peg-epo及间充质干细胞的组合物、药物及其制备方法 |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989007944A1 (en) * | 1988-02-24 | 1989-09-08 | American National Red Cross | Device for site directed neovascularization and method for same |
| US4992419A (en) * | 1987-05-09 | 1991-02-12 | Boehringer Mannheim Gmbh | Stabilized erythropoietin preparations |
| WO1992015323A1 (en) * | 1991-03-11 | 1992-09-17 | Creative Biomolecules, Inc. | Protein-induced morphogenesis |
| US5198417A (en) * | 1985-11-27 | 1993-03-30 | Genetics Institute, Inc. | Methods of treating pancytopenia and AIDS by co-administering EPO and colony stimulating factors |
| WO1998010650A1 (en) * | 1996-09-11 | 1998-03-19 | East Carolina University | Method of treating endothelial injury |
| US5980887A (en) * | 1996-11-08 | 1999-11-09 | St. Elizabeth's Medical Center Of Boston | Methods for enhancing angiogenesis with endothelial progenitor cells |
| WO2000061164A1 (en) * | 1999-04-13 | 2000-10-19 | Kenneth S. Warren Laboratories | Modulation of excitable tissue function by peripherally administered erythropoietin |
| WO2002014356A2 (en) * | 2000-08-11 | 2002-02-21 | Baxter Healthcare Sa | Therapeutic use of a recombinant erythropoietin having high activity and reduced side effects |
| US20020065214A1 (en) * | 2000-11-29 | 2002-05-30 | Adrian Iaina | Method of treating congestive heart failure |
| WO2002085940A2 (en) * | 2001-04-04 | 2002-10-31 | Genodyssee | New polynucleotides and polypeptides of the erythropoietin gene |
| WO2003037273A2 (en) * | 2001-11-01 | 2003-05-08 | University Of Utah Research Foundation | Method of use of erythropoietin to treat ischemic acute renal failure |
| WO2003057242A1 (en) * | 2002-01-09 | 2003-07-17 | Crucell Holland B.V. | Use of erythropoietin for the preventive or curative treatment of cardiac failure |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
| IL77081A (en) | 1984-12-04 | 1999-10-28 | Genetics Inst | Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin |
| US4732889A (en) | 1985-02-06 | 1988-03-22 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis |
| WO1987003204A1 (en) | 1985-11-27 | 1987-06-04 | Genetics Institute, Inc. | Treatment of aids-type disease |
| DK173067B1 (da) | 1986-06-27 | 1999-12-13 | Univ Washington | Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa |
| US5013718A (en) | 1986-11-21 | 1991-05-07 | Amgen, Inc. | Method for treating iron overload using EPO |
| US5024841A (en) * | 1988-06-30 | 1991-06-18 | Collagen Corporation | Collagen wound healing matrices and process for their production |
| DE4014654A1 (de) | 1990-05-08 | 1991-11-14 | Behringwerke Ag | Galenische waessrige formulierungen von erythropoietin und ihre verwendung |
| US5354934A (en) * | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
| US5888772A (en) | 1993-04-29 | 1999-03-30 | Abbott Laboratories | DNA encoding human a erythropoietin analog |
| CN1057534C (zh) | 1993-08-17 | 2000-10-18 | 柯瑞英-艾格公司 | 促红细胞生成素类似物 |
| JPH08205860A (ja) * | 1994-01-21 | 1996-08-13 | Usa Government | 造血細胞の膨大化および移植方法 |
| ITFI940106A1 (it) * | 1994-05-27 | 1995-11-27 | Menarini Ricerche Sud Spa | Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica |
| ES2206521T3 (es) | 1994-11-03 | 2004-05-16 | Roche Diagnostics Gmbh | Utilizacion de la eritropoyetina en el tratamiento de artritis reumatoide. |
| US5837675A (en) * | 1995-02-03 | 1998-11-17 | Brox; Alan G. | Synergistic effect of insulin-like growth factor-I and erythropoietin |
| US6284260B1 (en) | 1998-02-04 | 2001-09-04 | Veronica L. Zaharia Czeizler | Treatment with erythropoietin of bleeding from benign and malignant lesions with normal and abnormal coagulation parameters |
| US6274158B1 (en) * | 1998-02-04 | 2001-08-14 | Veronica L. Zaharia Czeizler | Treatment with recombinant human erythropoietin of bleeding in patients with normal and abnormal hemostasis |
| DE19857609A1 (de) | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
| EP1286690B1 (en) | 2000-05-02 | 2007-07-04 | Action Pharma A/S | Use of alpha-msh and epo for the manufacture of a medicament for preventing or treating ischemic conditions |
| US7259146B2 (en) * | 2000-05-26 | 2007-08-21 | Ortho-Mcneil Pharmaceutical, Inc. | Neuroprotective peptides |
| PA8536201A1 (es) | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
| CA2468499A1 (en) * | 2001-11-28 | 2003-06-05 | Ortho-Mcneil Pharmaceutical, Inc. | Erythropoietin dosing regimen for treating anemia |
| US6748154B2 (en) * | 2002-03-28 | 2004-06-08 | Nortel Networks Limited | Optical module access tray |
| DE10234192B4 (de) | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
| DE102004063927A1 (de) * | 2004-01-23 | 2005-12-15 | Epoplus Gmbh Co.Kg | Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden |
-
2002
- 2002-07-26 DE DE10234192A patent/DE10234192B4/de not_active Expired - Fee Related
-
2003
- 2003-07-25 HR HR20100187A patent/HRP20100187A2/xx not_active Application Discontinuation
- 2003-07-25 PL PL395151A patent/PL395151A1/pl unknown
- 2003-07-25 PT PT07001689T patent/PT1779862E/pt unknown
- 2003-07-25 AU AU2003255290A patent/AU2003255290B2/en not_active Ceased
- 2003-07-25 PT PT03766302T patent/PT1526867E/pt unknown
- 2003-07-25 SI SI200331837T patent/SI1779862T1/sl unknown
- 2003-07-25 WO PCT/EP2003/008229 patent/WO2004012759A2/de not_active Ceased
- 2003-07-25 UA UAA200501760A patent/UA85997C2/ru unknown
- 2003-07-25 US US10/522,426 patent/US7745387B2/en not_active Expired - Fee Related
- 2003-07-25 PL PL03374874A patent/PL374874A1/xx unknown
- 2003-07-25 DK DK07001689.4T patent/DK1779862T3/da active
- 2003-07-25 ES ES07001689T patent/ES2345673T3/es not_active Expired - Lifetime
- 2003-07-25 DK DK03766302T patent/DK1526867T3/da active
- 2003-07-25 CA CA002493598A patent/CA2493598A1/en not_active Abandoned
- 2003-07-25 CN CN2007101279144A patent/CN101099860B/zh not_active Expired - Fee Related
- 2003-07-25 EP EP03766302A patent/EP1526867B1/de not_active Expired - Lifetime
- 2003-07-25 MX MXPA05001120A patent/MXPA05001120A/es active IP Right Grant
- 2003-07-25 CN CNA038221160A patent/CN1681526A/zh active Pending
- 2003-07-25 HR HR20050065A patent/HRP20050065A2/hr not_active Application Discontinuation
- 2003-07-25 EA EA200500281A patent/EA009463B1/ru not_active IP Right Cessation
- 2003-07-25 KR KR1020107011097A patent/KR20100077033A/ko not_active Ceased
- 2003-07-25 HR HR20070189A patent/HRP20070189A2/xx not_active Application Discontinuation
- 2003-07-25 UA UAA200801307A patent/UA94913C2/ru unknown
- 2003-07-25 AT AT07001689T patent/ATE468132T1/de not_active IP Right Cessation
- 2003-07-25 CA CA2710100A patent/CA2710100A1/en not_active Abandoned
- 2003-07-25 EA EA200801236A patent/EA200801236A1/ru unknown
- 2003-07-25 AT AT03766302T patent/ATE360436T1/de not_active IP Right Cessation
- 2003-07-25 BR BR0312981-0A patent/BR0312981A/pt not_active IP Right Cessation
- 2003-07-25 ES ES03766302T patent/ES2285195T3/es not_active Expired - Lifetime
- 2003-07-25 JP JP2004525322A patent/JP4727988B2/ja not_active Expired - Fee Related
- 2003-07-25 DE DE50307140T patent/DE50307140D1/de not_active Expired - Lifetime
- 2003-07-25 DE DE50312729T patent/DE50312729D1/de not_active Expired - Lifetime
- 2003-07-25 EP EP10000381A patent/EP2191838A1/de not_active Withdrawn
- 2003-07-25 CN CN200710127913XA patent/CN101099731B/zh not_active Expired - Fee Related
- 2003-07-25 EP EP07001689A patent/EP1779862B1/de not_active Expired - Lifetime
- 2003-07-25 SI SI200330881T patent/SI1526867T1/sl unknown
- 2003-07-25 EA EA200700196A patent/EA013966B1/ru not_active IP Right Cessation
- 2003-07-25 KR KR1020057001341A patent/KR20050026513A/ko not_active Ceased
- 2003-07-25 SG SG2007003890A patent/SG177004A1/en unknown
-
2005
- 2005-01-06 IS IS7633A patent/IS2671B/is unknown
- 2005-01-20 IL IL16640105A patent/IL166401A0/xx not_active IP Right Cessation
- 2005-01-25 ZA ZA200500726A patent/ZA200500726B/xx unknown
- 2005-02-24 NO NO20051002A patent/NO20051002L/no not_active Application Discontinuation
-
2007
- 2007-07-02 CY CY20071100871T patent/CY1108052T1/el unknown
-
2009
- 2009-02-25 AU AU2009200748A patent/AU2009200748A1/en not_active Abandoned
- 2009-05-06 IS IS8817A patent/IS8817A/is unknown
-
2010
- 2010-03-18 IL IL204577A patent/IL204577A/en not_active IP Right Cessation
- 2010-04-13 US US12/759,299 patent/US20100247451A1/en not_active Abandoned
- 2010-04-13 US US12/759,321 patent/US20100247452A1/en not_active Abandoned
- 2010-04-13 US US12/759,275 patent/US20100247450A1/en not_active Abandoned
- 2010-07-02 IS IS8909A patent/IS8909A/is unknown
- 2010-07-09 JP JP2010157094A patent/JP2010280672A/ja not_active Withdrawn
- 2010-07-09 JP JP2010157093A patent/JP2010280671A/ja not_active Withdrawn
- 2010-07-09 JP JP2010157092A patent/JP2010280670A/ja not_active Withdrawn
- 2010-07-29 CY CY20101100712T patent/CY1110713T1/el unknown
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5198417A (en) * | 1985-11-27 | 1993-03-30 | Genetics Institute, Inc. | Methods of treating pancytopenia and AIDS by co-administering EPO and colony stimulating factors |
| US4992419A (en) * | 1987-05-09 | 1991-02-12 | Boehringer Mannheim Gmbh | Stabilized erythropoietin preparations |
| WO1989007944A1 (en) * | 1988-02-24 | 1989-09-08 | American National Red Cross | Device for site directed neovascularization and method for same |
| WO1992015323A1 (en) * | 1991-03-11 | 1992-09-17 | Creative Biomolecules, Inc. | Protein-induced morphogenesis |
| WO1998010650A1 (en) * | 1996-09-11 | 1998-03-19 | East Carolina University | Method of treating endothelial injury |
| US5980887A (en) * | 1996-11-08 | 1999-11-09 | St. Elizabeth's Medical Center Of Boston | Methods for enhancing angiogenesis with endothelial progenitor cells |
| WO2000061164A1 (en) * | 1999-04-13 | 2000-10-19 | Kenneth S. Warren Laboratories | Modulation of excitable tissue function by peripherally administered erythropoietin |
| WO2002014356A2 (en) * | 2000-08-11 | 2002-02-21 | Baxter Healthcare Sa | Therapeutic use of a recombinant erythropoietin having high activity and reduced side effects |
| US20020065214A1 (en) * | 2000-11-29 | 2002-05-30 | Adrian Iaina | Method of treating congestive heart failure |
| WO2002085940A2 (en) * | 2001-04-04 | 2002-10-31 | Genodyssee | New polynucleotides and polypeptides of the erythropoietin gene |
| WO2003037273A2 (en) * | 2001-11-01 | 2003-05-08 | University Of Utah Research Foundation | Method of use of erythropoietin to treat ischemic acute renal failure |
| WO2003057242A1 (en) * | 2002-01-09 | 2003-07-17 | Crucell Holland B.V. | Use of erythropoietin for the preventive or curative treatment of cardiac failure |
Non-Patent Citations (10)
| Title |
|---|
| BUEMI M. ET AL.: "Recombinant erythropoietin prevents the progression of atherosclerosis in Watanabe rabbits with hereditary hypocholesterolemia". NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. 12, no. 9, 1997, page A190, XP009021639 & ANNUAL CONGRESS OF THE EUROPEAN RENAL ASSOCIATION AND THE EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATI; GENEVA, SWITZERLAND; SEPTEMBER 21-24, 1997, ISSN: 0931-0509, abstract * |
| BUEMI M. ET AL.: "Recombinant human erythropoietin (rHuEPO): More than just the correction of uremic anemia". JOURNAL OF NEPHROLOGY, 2002 ITALY, vol. 15, no. 2, 2002, pages 97-103, XP009021789, ISSN: 1121-8428, page 99, column 1, page 101, column 1, page 101, column 2 * |
| DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 16 November 2001 (2001-11-16), ARCASOY MURAT O. ET AL.: "Erythropoietin (EPO) stimulates angiogenesis in vivo and promotes wound healing". XP002275417, Database accession no. PREV200200261552, abstract & BLOOD, vol. 98, no. 11, Part 1, 16 November, 2001 (2001-11-16), pages 822a-823a, 43RD ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, PART 1; ORLANDO, FLORIDA, USA; DECEMBER 07-11, 2001 ISSN: 0006-4971 * |
| DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1997, CONRAD KIRK P. ET AL.: "Placental cytokines and the pathogenesis of preeclampsia". XP002275414, Database accession no. PREV199799525116, abstract & AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, vol. 37, no. 3, 1997, pages 240-249, ISSN: 1046-7408 * |
| DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 1998 (1998-11), ALVAREZ ARROYO MARIA VICTORIA ET AL.: "Role of vascular endothelial growth factor on erythropoietin-related endothelial cell proliferation". XP002275418, Database accession no. PREV199800506855, abstract & JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 9, no. 11, November 1998 (1998-11), pages 1998-2004, ISSN: 1046-6673 * |
| DATABASE EMBASE 'Online! ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 2000, CASES A: "Recombinant human erythropoietin treatment in chronic renal failure: Effects on hemostasis and vasculature". XP002275415, Database accession no. EMB-2000364537, abstract & DRUGS OF TODAY, 2000, SPAIN, vol. 36, no. 8, 2000, pages 541-556, ISSN: 0025-7656 * |
| DATABASE MEDLINE 'Online! US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; May 1996 (1996-05), BRAGA J. ET AL.: "Maternal and perinatal implications of the use of human recombinant erythropoietin.", XP002275416, Database accession no. NLM8677769, abstract & ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA. MAY 1996, vol. 75, no. 5, May 1996 (1996-05), pages 449-3, ISSN: 0001-6349 * |
| KRAUSE K. ET AL.: "Recombinant human erythropoietin and VEGF have equal angiogenic potency: Investigation in a novel in vitro assay of human vascular tissues". EUROPEAN HEART JOURNAL, vol. 22, no. Abstract Supplement, September 2001 (2001-09), page 154, XP001097312 & XXIII CONGRESS OF THE EUROPEAN SOCIETY OF CARDIOLOGY TOGETHER WITH THE 36TH ANNUAL GENERAL MEETING O; STOCKHOLM, SWEDEN; SEPTEMBER 01-05, 2001, ISSN: 0195-668X, abstract * |
| MASCHIO G.: "Erythropoietin and systemic hypertension". NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. 10, no. SUPPL. 2, 1995, pages 74-79, XP009021640 & ISSN: 0931-0509, abstract * |
| MASUDA SEIJI ET AL.: "Erythropoietic, neurotrophic, and angiogenic functions of erythropoietin and regulation of erythropoietin production". INTERNATIONAL JOURNAL OF HEMATOLOGY, vol. 70, no. 1, July 1999 (1999-07), pages 1-6, XP009021621 & ISSN: 0925-5710, page 3, column 2, paragraph 3-page 4, column 1, paragraph 3; figure 1 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2642302C1 (ru) * | 2009-08-13 | 2018-01-24 | Акселерон Фарма Инк. | Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA009463B1 (ru) | Применение эритропоэтина | |
| AU2010200621A1 (en) | Use of low-dose erythropoietin for stimulation of endothelial progenitor cells, for organ regeneration and for slowing the progression of end-organ damage | |
| JP6397122B2 (ja) | 血管新生関連疾患を治療するためのペプチドの使用 | |
| NZ553426A (en) | Use of erythropoietin for treating diabetes mellitus | |
| MXPA06008181A (en) | Use of low-dose erythropoietin for the treatment of acute or chronic kidney failure and for the treatment of wounds | |
| RU2795320C2 (ru) | Терапевтическое средство для лечения кардиомиопатии, перенесенного инфаркта миокарда и хронической сердечной недостаточности | |
| HK1108625B (en) | Erythropoietin in subpolycythemic doses for treating diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KZ KG MD TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): BY RU |